Business
UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that it has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB's epilepsy portfolio. Neurona Therapeutics is a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for epilepsies and other disorders of the nervous system.
About this update from United Community Banks, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Acquisition builds on UCB's 30-year heritage and leadership as an innovator in epilepsy and accelerates entry into next generation disease-modifying therapies.","length":163,"tagName":"p"}]},{"val":[{"type":"text","content":"Lead investigational asset, NRTX-1001, a neuronal cell therapy, is being evaluated in phase I/II clinical trials for drug-resistant mesial temporal lobe epilepsy1 2","length":164,"tagName":"p"}]},{"val":[{"type":"text","content":"Temporal lobe epilepsy – the most common type of focal epilepsy - remains a high burden condition with significant unmet need, affecting memory, emotion, behavior, and daily functioning.","length":186,"tagName":"p"}]},{"val":[{"type":"text","content":"Total transaction value of up to US $1.15b consisting of a US $650m upfront payment plus up to US $500m in potential future milestone payments.","length":143,"tagName":"p"}]},{"val":[{"type":"text","content":"2026 revenue guidance remains unchanged. 2026 underlying profitability, as measured by adjusted EBITDA, is now expected to grow in a high single‑digit to mid‑teens percentage range at constant exchange rates (CER).","length":214,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":870,"olType":false},{"type":"text","content":"ATLANTA, April 17, 2026 /PRNewswire/ -- UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that it has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB's epilepsy portfolio. Neurona Therapeutics is a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for epilepsies and other disorders of the nervous system.","length":470,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/UCB, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/UCB, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":95,"url":"https://media.zenfs.com/en/prnewswire.com/b8934a241b3f4be76014bb4ac3438a0c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HjbSkPCfjBQlXsmp4Za4Jg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE2Nw--/https://media.zenfs.com/en/prnewswire.com/b8934a241b3f4be76014bb4ac3438a0c","width":400,"height":95}},"href":"https://mma.prnewswire.com/media/677397/With_Tag_Logo.html","hrefEx...